1. Bartlett RR, Dimitrijevic M, Mattar T, Zielinski T, Germann T, Rude E, et al. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions 1991;32:10–21.
2. Zielinski T, Herrmann M, Muller HJ, Riedel N, Bartlett RR. The influence of leflunomide on cell cycle, IL-2-receptor (IL-2-r) and its gene expression. Agents Actions 1994;41:205.
3. Ulrichs K, Kaitschick J, Bartlett R, Muller Ruchholtz W. Suppression of natural xenophile antibodies with the novel immunomodulating drug leflunomide. Transplant Proc 1992;24:718–9.
4. Williams JW, Xiao F, Foster PF, Chong A, Sharma S, Bartlett R, et al. Immunosuppressive effects of leflunomide in a cardiac allograft model. Transplant Proc 1993;25:745–6.
5. Schorlemmer HU, Weiler FR, Bartlett RR. Prolongation of allogeneic transplanted skin grafts and induction of tolerance by leflunomide, a new immunosuppressive isoxazole derivative. Transplant Proc 1993;25:763–7.